Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06690827 | Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN | PHASE1 | RECRUITING | 30 | — | — | Nov 13, 2024 | Oct 30, 2028 | Nov 15, 2024 | 1 | China |
The incidence of adverse events after CAR-NK cell infusion was assessed by CTCAE, version 5.0.
| Arm | Type | Description |
|---|---|---|
| CD123 CAR-NK cells | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Anti-CD123 CAR NK cells | DRUG | Each patient will receive two CAR-NK cell infusions at D0 and D7, and CAR-NK cells need to be controlled within 70 minutes from thawing to infusion completion. |
Inclusion Criteria: 1. Patients of any gender, aged between 18 and 75 years (inclusive); 2. Positive expression of CD123 on tumor cells detected by flow cytometry; 3. Patients with a confirmed diagnosis of CD123-positive relapsed/refractory AML or BPDCN: (1) For AML patients： * Relapsed refers to...